Last reviewed · How we verify
HR20013 for injection；dexamethasone
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and allergic conditions, Cerebral edema, Adrenocortical insufficiency.
At a glance
| Generic name | HR20013 for injection；dexamethasone |
|---|---|
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone acts as a potent corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene production, and suppresses T-cell and B-cell proliferation. It decreases capillary permeability and stabilizes lysosomal membranes, thereby reducing inflammatory cell migration and mediator release. The drug is commonly used for its anti-inflammatory and immunosuppressive properties across multiple therapeutic contexts.
Approved indications
- Inflammatory and allergic conditions
- Cerebral edema
- Adrenocortical insufficiency
- Shock (septic, anaphylactic)
- Autoimmune disorders
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (euphoria, depression)
- Immunosuppression / increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
Key clinical trials
- Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors (PHASE3)
- Study of HR20013 for Injection in Patients With Malignant Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |